Tulavi Therapeutics Broadens Indication for allay™ Hydrogel Cap to Benefit Smaller Patients

Tulavi Therapeutics Expands Indication for allay™ Hydrogel Cap

Tulavi Therapeutics, a private firm devoted to revolutionizing surgical solutions, has taken a significant step towards improving patient care in peripheral nerve surgery. On October 7, 2025, the company revealed that it is broadening the indication of its allay™ Hydrogel Cap to include patients who weigh as little as 25 kilograms (55 pounds). This new development allows for smaller patients, who are at risk of developing symptomatic neuromas due to trauma or amputation, to benefit from this innovative product.

What is the allay™ Hydrogel Cap?

The allay™ Hydrogel Cap is a unique medical device made from a fully absorbable material that forms an in situ hydrogel barrier around the transected nerve. By providing a protective cover, it supports nerve recovery and significantly reduces the likelihood of symptomatic neuroma formation, which can lead to debilitating pain and complications. Once in place, the hydrogel cap remains effective for nearly eight months, shielding the nerve and preventing axonal escape during critical healing moments.

Dr. Josh Vose, CEO of Tulavi Therapeutics, states, "Surgeons now have a trusted solution for nerve protection and reducing the risk of symptomatic neuroma formation in patients as small as 25 kg. We are proud to extend the benefits of the allay Hydrogel Cap to this broader population – who suffer the same debilitating injuries as older and larger individuals – so they may benefit equally."

Addressing Critical Needs in Surgical Solutions

This expansion reflects Tulavi's commitment to addressing significant unmet needs in peripheral nerve surgery. Traditionally, there has been a lack of specialized solutions for smaller patients, who might experience the same traumatic injuries as larger patients but had limited options for treatment. Tulavi striving to close this gap emphasizes its dedication to ensuring that innovations in surgical technology are accessible to all patients, regardless of their size.

The Journey Ahead

Tulavi Therapeutics is based in Los Gatos, California, and has dedicated itself to redefining peripheral nerve surgery. Through continual innovation, the company aims to enhance patient outcomes and raise the standard of care for surgeons addressing peripheral nerve conditions. The announcement regarding the allay™ Hydrogel Cap represents a milestone in this journey, marking a significant advancement in how nerve repair and protection is approached.

With this expanded indication, Tulavi is poised to make a substantial impact in the field of neurosurgery by empowering surgeons with innovative tools to ensure better outcomes for all of their patients, including those who are often overlooked in typical surgical scenarios.

In conclusion, the allay™ Hydrogel Cap not only embodies Tulavi's dedication to patient care but also illustrates the importance of customizing medical solutions to meet the diverse needs of various patient populations, ultimately facilitating recovery and improving overall quality of life.